Newborn blood spot screening: New opportunities, old problems

@article{Pollitt2009NewbornBS,
  title={Newborn blood spot screening: New opportunities, old problems},
  author={Rodney J. Pollitt},
  journal={Journal of Inherited Metabolic Disease},
  year={2009},
  volume={32},
  pages={395-399}
}
  • R. Pollitt
  • Published 4 May 2009
  • Medicine
  • Journal of Inherited Metabolic Disease
SummaryNewborn screening is evolving very rapidly. Geographical coverage is expanding, particularly for common disorders such as congenital hypothyroidism. New technologies, particularly tandem mass spectrometry and high throughput mutation analysis, have increased greatly the range of disorders which could be covered. However, these new possibilities are being exploiting at very different rates in different countries. This is due in part to the different ways in which generally-accepted… 
Newborn screening.
  • J. Pitt
  • Medicine
    The Clinical biochemist. Reviews
  • 2010
TLDR
This review focuses on Australasian NBS practices and testing for primary hypothyroidism and cystic fibrosis, which was the prototype disorder for newborn screening (NBS), and multiplex testing for approximately 25 inborn errors of metabolism using tandem mass spectrometry.
New technologies extend the scope of newborn blood‐spot screening, but old problems remain unresolved
The potential of newborn blood‐spot screening is expanding rapidly with the development of new analytical techniques and treatment methods. At the same time, some existing programmes, particularly
Newborn screening from an international perspective--different countries, different approaches.
Expanded newborn screening: social and ethical issues
  • J. Dhondt
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2010
TLDR
Newborn screening and genetic testing have expanded rapidly in the last decade with the advent of multiplex technologies and/or DNA technologies, but screening panels include a large number of disorders, which may not meet all of the traditional screening criteria.
Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry
  • T. Ozben
  • Medicine
    Clinical chemistry and laboratory medicine
  • 2013
TLDR
This review covers some of the basic theory of expanded MS/MS and follow-up confirmatory tests applied for NBS of IEM, a coordinated comprehensive system consisting of education, screening, follow- up of abnormal test results, confirmatory testing, diagnosis, treatment, and evaluation of periodic outcome and efficiency.
Implementing genetic tests: infertility and newborn bloodspot screening
TLDR
Research into different perspectives on genetic information in health care finds that genetic information on an effective immune response against pathogens in the female reproductive organ may allow the diagnosis of infertility to be made more accurately.
International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents
TLDR
The analyses presented in this article highlight that despite programs' commonalities, no one 'DBS decision-making solution' exists and provides an objective starting point for structured decision- making approaches for DBS programs.
Pharmacotherapy of inborn errors of metabolism illustrating challenges in orphan diseases.
  • A. Das
  • Medicine, Biology
    Journal of pharmacological and toxicological methods
  • 2016
Policy Making in Newborn Screening Needs a Structured and Transparent Approach
TLDR
There are a wave of issues facing NBS programs that policy makers must take into account when developing policy processes, and issues pertinent to NBS policy making are explored through the lens of the policy cycle.
Commentary on ‘Newborn screening for cystic fibrosis’, with a response from the review authors
This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: Southern KW, Merelle ME, Dankert-Roelse JE, Nagelkerke A. Newborn screening for cystic fibrosis.
...
...

References

SHOWING 1-10 OF 49 REFERENCES
Newborn screening for cystic fibrosis: Techniques and strategies
  • B. Wilcken
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2007
SummaryNewborn screening for cystic fibrosis has been carried out for over 25 years, and clinical and cost benefits have been documented. There is still much variation in the methods and strategies
The consequences of extended newborn screening programmes: Do we know who needs treatment?
  • B. Wilcken
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2008
TLDR
Particular problems are seen with disorders that were previously thought very rare but are now found frequently by newborn screening, and in the present state of knowledge should clearly not be included in routine newborn screening panels.
International perspectives on newborn screening
  • R. Pollitt
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2006
TLDR
Alternative, less categorical, approaches are needed: the disorders concerned are not homogeneous entities and there may be advantages to screening other than reducing morbidity or mortality.
Medical Backup Needed for Newborn Metabolic Screening Programs
TLDR
While the technology of screening continues to expand, the development of medical backup services has lagged and the reasons for this are explored and recommendations for change are made.
Newborn screening for methylmalonic acidurias—Optimization by statistical parameter combination
TLDR
The results of a new statistical approach to identify parameter combinations that allow for 100% sensitivity as well as increased specificity for newborn screening for disorders of propionate metabolism are reported.
Neonatal screening: from the ‘Guthrie age’ to the ‘genetic age’
  • J. Dhondt
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2007
TLDR
The purpose of this paper is to present some of the major problems that screening programmes will face in the near future.
Newborn bloodspot screening in the UK – past, present and future
TLDR
The UK has lagged behind many other European countries in the application of tandem mass spectrometry (MS-MS) though, following a major pilot study, screening for medium-chain acyl-CoA dehydrogenase deficiency is now in the process of introduction.
Organization of a Regional Newborn Screening Laboratory
TLDR
Any newborn screening program and laboratory should be organized in such a manner as to allow for continuous expansion of tests as new methods for detection and treatment are developed.
Expanded newborn screening in Europe 2007
TLDR
An overview of the current status of expanded newborn screening programmes in Europe and the reasons for the differences observed appear arbitrary and contrary to the optimal benefit of this important preventive health measure are presented.
International cooperation in the expansion of a newborn screening programme in Lebanon: a possible model for other programmes
SummaryTandem mass spectrometry (MS/MS) is rapidly gaining support, even in less-developed nations, as the method of choice for the newborn screening of metabolic disorders, although difficulties in
...
...